Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTech

Biogen AAIC
The agreement includes up to $32 million in upfront and research milestone payments. (James Waldron)

TrimTech Therapeutics has been tapped by Biogen in a $411 million biobucks collaboration to develop protein degraders for neurodegenerative diseases.

The agreement includes up to $32 million in upfront and research milestone payments, with the full deal value taking account of additional milestones further down the line. In return, Biogen gets an exclusive global license to the resulting small molecule protein degraders developed using TrimTech’s technology.

Cambridge, U.K.-based TrimTech uses its platform based on the E3-ligase TRIM21 to clear disease-causing protein aggregates. Its degraders include the bispecific chimeric molecules called TRIMTAC and the mutual binding facilitator TRIMGLUE. These potentially provide an alternative to the more common bivalent degraders called PROTACs.

The company, a 2025 inductee into Fierce Biotech’s Fierce 15, has named neurodegenerative diseases such as Huntington’s, Alzheimer’s and Parkinson’s as potential targets.

That puts TrimTech right in Biogen’s wheelhouse as a leader in neurodegenerative R&D, particularly in Alzheimer’s, where the company and its partner Eisai brought two drugs over the regulatory finish line in recent years, including the monoclonal antibody Leqembi.

Founded in 2023, TrimTech’s dance card had been filled with Big Pharma names ahead of the Biogen deal, with giants like Johnson & Johnson, Eli Lilly and Pfizer participating in a seed round totaling $47 million earlier this year. The protein degrader space has attracted a good deal of attention from drugmakers looking to fulfill the promise of these protein-clearing candidates in areas such as cancer, inflammation and neurodegeneration.

“This is a significant validation of the progress we have made and the potential of our TRIM21-based targeted protein degradation platforms,” TrimTech CEO Nicki Thompson, Ph.D., said in a release. “Combining our treatments for neurodegenerative diseases brings new promise to the potential for delivering more effective therapies for patients.”